1p45
From Proteopedia
| Line 1: | Line 1: | ||
[[Image:1p45.gif|left|200px]] | [[Image:1p45.gif|left|200px]] | ||
| - | + | <!-- | |
| - | + | The line below this paragraph, containing "STRUCTURE_1p45", creates the "Structure Box" on the page. | |
| - | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
| - | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |
| - | + | or leave the SCENE parameter empty for the default display. | |
| - | + | --> | |
| - | + | {{STRUCTURE_1p45| PDB=1p45 | SCENE= }} | |
| - | | | + | |
| - | + | ||
| - | }} | + | |
'''Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data''' | '''Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data''' | ||
| Line 23: | Line 20: | ||
==Reference== | ==Reference== | ||
Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data., Kuo MR, Morbidoni HR, Alland D, Sneddon SF, Gourlie BB, Staveski MM, Leonard M, Gregory JS, Janjigian AD, Yee C, Musser JM, Kreiswirth B, Iwamoto H, Perozzo R, Jacobs WR Jr, Sacchettini JC, Fidock DA, J Biol Chem. 2003 Jun 6;278(23):20851-9. Epub 2003 Feb 26. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/12606558 12606558] | Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data., Kuo MR, Morbidoni HR, Alland D, Sneddon SF, Gourlie BB, Staveski MM, Leonard M, Gregory JS, Janjigian AD, Yee C, Musser JM, Kreiswirth B, Iwamoto H, Perozzo R, Jacobs WR Jr, Sacchettini JC, Fidock DA, J Biol Chem. 2003 Jun 6;278(23):20851-9. Epub 2003 Feb 26. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/12606558 12606558] | ||
| - | [[Category: Enoyl-[acyl-carrier-protein] reductase (NADH)]] | ||
[[Category: Mycobacterium tuberculosis]] | [[Category: Mycobacterium tuberculosis]] | ||
[[Category: Single protein]] | [[Category: Single protein]] | ||
| Line 44: | Line 40: | ||
[[Category: TBSGC, TB Structural Genomics Consortium.]] | [[Category: TBSGC, TB Structural Genomics Consortium.]] | ||
[[Category: Yee, C.]] | [[Category: Yee, C.]] | ||
| - | [[Category: | + | [[Category: Enoyl-acp reductase]] |
| - | [[Category: | + | [[Category: Inha]] |
| - | [[Category: | + | [[Category: Protein structure initiative]] |
| - | [[Category: | + | [[Category: Psi]] |
| - | [[Category: | + | [[Category: Rossmann fold]] |
| - | [[Category: | + | [[Category: Short chain dehydrogenase reductase]] |
| - | [[Category: | + | [[Category: Structural genomic]] |
| - | [[Category: | + | [[Category: Tb structural genomics consortium]] |
| - | [[Category: | + | [[Category: Tbsgc]] |
| - | [[Category: | + | [[Category: Triclosan]] |
| - | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 04:39:35 2008'' | |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | |
Revision as of 01:39, 3 May 2008
Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data
Overview
Tuberculosis and malaria together result in an estimated 5 million deaths annually. The spread of multidrug resistance in the most pathogenic causative agents, Mycobacterium tuberculosis and Plasmodium falciparum, underscores the need to identify active compounds with novel inhibitory properties. Although genetically unrelated, both organisms use a type II fatty-acid synthase system. Enoyl acyl carrier protein reductase (ENR), a key type II enzyme, has been repeatedly validated as an effective antimicrobial target. Using high throughput inhibitor screens with a combinatorial library, we have identified two novel classes of compounds with activity against the M. tuberculosis and P. falciparum enzyme (referred to as InhA and PfENR, respectively). The crystal structure of InhA complexed with NAD+ and one of the inhibitors was determined to elucidate the mode of binding. Structural analysis of InhA with the broad spectrum antimicrobial triclosan revealed a unique stoichiometry where the enzyme contained either a single triclosan molecule, in a configuration typical of other bacterial ENR:triclosan structures, or harbored two triclosan molecules bound to the active site. Significantly, these compounds do not require activation and are effective against wild-type and drug-resistant strains of M. tuberculosis and P. falciparum. Moreover, they provide broader chemical diversity and elucidate key elements of inhibitor binding to InhA for subsequent chemical optimization.
About this Structure
1P45 is a Single protein structure of sequence from Mycobacterium tuberculosis. Full crystallographic information is available from OCA.
Reference
Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data., Kuo MR, Morbidoni HR, Alland D, Sneddon SF, Gourlie BB, Staveski MM, Leonard M, Gregory JS, Janjigian AD, Yee C, Musser JM, Kreiswirth B, Iwamoto H, Perozzo R, Jacobs WR Jr, Sacchettini JC, Fidock DA, J Biol Chem. 2003 Jun 6;278(23):20851-9. Epub 2003 Feb 26. PMID:12606558 Page seeded by OCA on Sat May 3 04:39:35 2008
Categories: Mycobacterium tuberculosis | Single protein | Alland, D. | Fidock, D A. | Gourlie, B B. | Gregory, J S. | Iwamoto, H. | Janjigian, A D. | Jr., W R.Jacobs. | Kreiswirth, B N. | Kuo, M R. | Leonard, M. | Morbidoni, H R. | Musser, J M. | Perozzo, R. | Sacchettini, J C. | Sneddon, S F. | Staveski, M M. | TBSGC, TB Structural Genomics Consortium. | Yee, C. | Enoyl-acp reductase | Inha | Protein structure initiative | Psi | Rossmann fold | Short chain dehydrogenase reductase | Structural genomic | Tb structural genomics consortium | Tbsgc | Triclosan
